PL448716A1 - Kopolimer blokowy funkcjonalizowany fotoprzełącznikiem aryloazopirazolowym o fotoprzełączalnej aktywności antykoagulacyjnej i zastosowanie polimeru blokowego - Google Patents

Kopolimer blokowy funkcjonalizowany fotoprzełącznikiem aryloazopirazolowym o fotoprzełączalnej aktywności antykoagulacyjnej i zastosowanie polimeru blokowego

Info

Publication number
PL448716A1
PL448716A1 PL448716A PL44871624A PL448716A1 PL 448716 A1 PL448716 A1 PL 448716A1 PL 448716 A PL448716 A PL 448716A PL 44871624 A PL44871624 A PL 44871624A PL 448716 A1 PL448716 A1 PL 448716A1
Authority
PL
Poland
Prior art keywords
application
arylazolyrazole
photoswitchable
photoswitch
block copolymer
Prior art date
Application number
PL448716A
Other languages
English (en)
Inventor
Nastassia Zhioba
Marta Stolarek
Krzysztof SZCZUBIAŁKA
Andrzej MOGIELNICKI
Bartłomiej Kałaska
Aleksandra FRĄCKIEWICZ
Dariusz PAWLAK
Original Assignee
Uniwersytet Jagielloński
Uniwersytet Medyczny W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński, Uniwersytet Medyczny W Białymstoku filed Critical Uniwersytet Jagielloński
Priority to PL448716A priority Critical patent/PL448716A1/pl
Priority to PCT/PL2025/050046 priority patent/WO2025250029A1/en
Publication of PL448716A1 publication Critical patent/PL448716A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/14—Esterification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2438/00—Living radical polymerisation
    • C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest kopolimer blokowy poli(sulfonianu styrenu) sodowego i kwasu poliakrylowego funkcjonalizowany podstawnikiem fenyloazopirazolowym określony wzorem (1). Zgłoszenie obejmuje również zastosowanie kopolimeru w farmacji, zwłaszcza do kontrolowania procesu krzepnięcia krwi oraz jego zastosowanie w leczeniu lub zapobieganiu chorób wymagających kontrolowania procesu krzepnięcia krwi.
PL448716A 2024-05-29 2024-05-29 Kopolimer blokowy funkcjonalizowany fotoprzełącznikiem aryloazopirazolowym o fotoprzełączalnej aktywności antykoagulacyjnej i zastosowanie polimeru blokowego PL448716A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL448716A PL448716A1 (pl) 2024-05-29 2024-05-29 Kopolimer blokowy funkcjonalizowany fotoprzełącznikiem aryloazopirazolowym o fotoprzełączalnej aktywności antykoagulacyjnej i zastosowanie polimeru blokowego
PCT/PL2025/050046 WO2025250029A1 (en) 2024-05-29 2025-05-29 A block copolymer functionalized with an arylazopyrazole photoswitch with photoswitchable anticoagulant activity and the use of the block polymer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL448716A PL448716A1 (pl) 2024-05-29 2024-05-29 Kopolimer blokowy funkcjonalizowany fotoprzełącznikiem aryloazopirazolowym o fotoprzełączalnej aktywności antykoagulacyjnej i zastosowanie polimeru blokowego

Publications (1)

Publication Number Publication Date
PL448716A1 true PL448716A1 (pl) 2025-12-01

Family

ID=96502829

Family Applications (1)

Application Number Title Priority Date Filing Date
PL448716A PL448716A1 (pl) 2024-05-29 2024-05-29 Kopolimer blokowy funkcjonalizowany fotoprzełącznikiem aryloazopirazolowym o fotoprzełączalnej aktywności antykoagulacyjnej i zastosowanie polimeru blokowego

Country Status (2)

Country Link
PL (1) PL448716A1 (pl)
WO (1) WO2025250029A1 (pl)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2098256B1 (en) * 2006-11-17 2016-06-08 National Cerebral and Cardiovascular Center Blood-coagulation inhibiting material, coating material and in vivo indwelling members made by using the material, and method of treatment
CA2964454A1 (en) * 2014-10-13 2016-04-21 Novabone Products, Llc Irrigation resistant compositions for regeneration of hard tissues and methods and kits of using the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HENG PHO YAP ET AL.: "Langmuir 2008, 24, 16, 8981–8990; https://doi.org/10.1021/la8011074", SYNTHESIS, MULTILAYER FILM ASSEMBLY, AND CAPSULE FORMATION OF MACROMOLECULARLY ENGINEERED ACRYLIC ACID AND STYRENE SULFONATE BLOCK COPOLYMERS *
MARTA STOLAREK ET AL.: "J. Med. Chem. 2023, 66, 3, 1778–1789; https://doi.org/10.1021/acs.jmedchem.2c01616", BIOLOGICAL PROPERTIES OF HEPARINS MODIFIED WITH AN ARYLAZOPYRAZOLE-BASED PHOTOSWITCH *
NAHAIN, A. A. ET AL.: "Biomacromolecules, 21(2), 1009-1021, (2020); abstract; https://doi.org/10.1021/acs.biomac.9b01688", ANTICOAGULANT HEPARIN MIMETICS VIA RAFT POLYMERIZATION *
ZHAO-YANG ZHANG ET AL.: "Chem. Eur. J. 2019, 25, 13402 – 13410; DOI: 10.1002/chem.201902897", PYRAZOLYLAZOPHENYL ETHER-BASED PHOTOSWITCHES: FACILE SYNTHESIS, (NEAR-)QUANTITATIVE PHOTOCONVERSION, LONG THERMAL HALF-LIFE, EASY FUNCTIONALIZATION, AND VERSATILE APPLICATIONS IN LIGHT-RESPONSIVE SYSTEMS *

Also Published As

Publication number Publication date
WO2025250029A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
Widgerow Chronic wound fluid—thinking outside the box
Patel et al. Left ventricular assist systems and infection-related outcomes: a comprehensive analysis of the MOMENTUM 3 trial
Fricker et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin®) in the prophylaxis of thromboembolic complications of abdominal oncological surgery
Allon et al. Effect of change in vascular access on patient mortality in hemodialysis patients
Humphries et al. Wide excision and healing by secondary intent for the surgical treatment of hidradenitis suppurativa: a single-center experience
Gold et al. Hypochlorous acid gel technology—Its impact on postprocedure treatment and scar prevention
US9056127B2 (en) Hydrogel composition based on co-polymer carrying multiple pendant sulphonic groups for use as a wound dressing
PL448716A1 (pl) Kopolimer blokowy funkcjonalizowany fotoprzełącznikiem aryloazopirazolowym o fotoprzełączalnej aktywności antykoagulacyjnej i zastosowanie polimeru blokowego
Goldsborough et al. Prevalence of leg wound complications after coronary artery bypass grafting: determination of risk factors
McLeod et al. Reliability of transport medium in the laboratory evaluation of corneal ulcers
Mungall et al. A prospective randomized comparison of the accuracy of computer‐assisted versus GUSTO nomogram‐directed heparin therapy
Velmahos et al. Wound management after colon injury: open or closed? A prospective randomized trial
Sharfman et al. Balancing thromboprophylaxis and bleeding in total joint arthroplasty: impact of eliminating enoxaparin and predonation and implementing pneumatic compression and tranexamic acid
Ricketts et al. Chemical injuries: the Tasmanian burns unit experience
Kitchens Disseminated intravascular coagulation
US20100143478A1 (en) Treatment of inflammation and the complement and kinin cascades in a patient, particularly in chronic ulcerous skin lesions
Smith et al. A randomized trial of biofilm dressing for venous leg ulcers
RU2649785C1 (ru) Антисептическая композиция, содержащая поливинилпирролидон и унитиол, применение такой композиции и способ обработки ран с ее использованием
EP2120973A1 (en) Modulation of proteases. particularly in the treatment of chronic ulcerous skin lesions
Thompson et al. An overview of wound healing and exudate management.
FR2837699B1 (fr) Composition cosmetique contenant un agent tensioactif cationique, un polymere cationique et un copolymere acrylique sequence, ramifie, amphiphile et procede de traitement.
Lunan Topical treatment of the burn patient
Günday et al. Is there a difference between two different skin disinfection methods in cardiac surgery in terms of isolated pathogens?
Safoev et al. The effectiveness of an electro activated water solution in the treatment of purulent diseases of soft tissues on an outpatient basis
Mureșan et al. A single-center prospective study on the efficiency of negative pressure wound therapy versus conventional wound therapy in the postoperative management of devitalized and infected wounds